Edwards Lifesciences Corp (EW)

84.36 -2.82 (-3.24%)

As of 2026-03-03 12:05:11 EST

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility completed in 2021 in Limerick, Ireland.

Traded asNYSE: EW
ISINUS28176E1082
CIK0001099800
LEIYA13X31F3V31L8TMPR58
EIN364316614
SectorMedical technology
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
CEOBernard J. Zovighian
Employees15,800
Fiscal Year End1231
AddressONE EDWARDS WAY, IRVINE, CA, 92614
Phone9492502500
Websitehttp://edwards.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
EWEdwards Lifesciences Corp2026-03-03 12:05:1184.36-2.82-3.24
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
EW0001099800Edwards Lifesciences CorpUS28176E1082YA13X31F3V31L8TMPR58364316614NYSE3842Orthopedic, Prosthetic & Surgical Appliances & Supplies1231DEONE EDWARDS WAYIRVINECA92614UNITED STATESUS9492502500ONE EDWARDS WAY, IRVINE, CA, 92614ONE EDWARDS WAY, IRVINE, CA, 92614CVG CONTROLLED INCMedical technology1958Bernard J. Zovighian15,800http://edwards.com45,899,189,298658,700,000580,800,000Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility completed in 2021 in Limerick, Ireland.2026-02-26 15:28:12
This is a preview of the latest data. Subscribe to access the full data.
EW Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
EW Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202545,899,189,298-9,625,820,648-17.336580,800,000-7,100,000-1.2077
202455,525,009,946-1,324,814,119-2.3304587,900,000-13,400,000-2.2285
202356,849,824,065-1,603,821,937-2.7438601,300,000-7,013,396-1.1529
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Mr. BoboCorporate Vice President2024737,0544,0001,229,450576,13151,9323,747,609
Mr. ChopraCorporate Vice President2024627,34601,284,500556,13353,7793,720,491
Mr. ZovighianDirector, Chief Executive Officer20241,133,84606,147,2501,451,58898,02814,579,474
Mr. UllemChief Financial Officer, Corporate Vice President2024774,33302,032,263525,93870,0885,303,183
Mr. WoodCorporate Vice President, Group President2024778,50001,601,038656,37072,6154,608,661
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202516,000
202415,800
202319,800
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue6,067,600,0005,439,500,0006,004,800,000
Cost Of Revenue1,334,200,0001,117,500,0001,379,800,000
Gross Profit4,733,400,0004,322,000,0004,625,000,000
Research And Development Expenses1,079,200,0001,053,000,0001,071,800,000
General And Administrative Expenses2,085,200,0001,789,200,0001,824,600,000
Operating Expenses2,028,500,0001,886,800,0001,920,900,000
Operating Income1,264,200,0001,378,700,0001,534,100,000
Net Income1,073,500,0004,174,600,0001,402,400,000
Earnings Per Share Basic1.846.982.31
Earnings Per Share Diluted1.836.972.3
Weighted Average Shares Outstanding Basic584,800,000597,700,000606,700,000
Weighted Average Shares Outstanding Diluted585,800,000599,300,000609,400,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents2,938,000,0003,045,200,0001,144,000,000
Marketable Securities Current39,100,00057,900,00064,500,000
Accounts Receivable659,600,000609,100,000775,100,000
Inventories1,126,200,0001,086,700,0001,168,200,000
Non Trade Receivables314,800,000293,900,00061,800,000
Other Assets Current339,300,000347,600,000239,300,000
Total Assets Current6,738,900,0006,285,400,0004,035,700,000
Marketable Securities Non Current278,600,000307,900,000583,900,000
Property Plant And Equipment1,811,900,0001,686,000,0001,749,400,000
Other Assets Non Current730,200,000721,600,000463,700,000
Total Assets Non Current1,914,600,0001,784,200,0001,843,400,000
Total Assets13,697,200,00013,055,300,0009,363,200,000
Accounts Payable227,500,000197,400,000201,400,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current192,500,000286,600,00059,300,000
Total Liabilities Current1,813,700,0001,505,200,0001,195,400,000
Long Term Debt598,300,000597,700,000597,000,000
Other Liabilities Non Current362,300,000357,500,000264,300,000
Total Liabilities Non Current1,545,900,0001,487,200,0001,448,400,000
Total Liabilities3,359,600,0002,992,400,0002,643,800,000
Common Stock658,700,000654,800,000650,500,000
Retained Earnings14,240,500,00013,167,000,0008,992,400,000
Accumulated Other Comprehensive Income-238,300,000-244,500,000-242,800,000
Total Shareholders Equity10,337,600,0009,998,400,0006,650,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization156,600,000155,200,000144,900,000
Share Based Compensation Expense158,100,000162,300,000139,400,000
Other Non Cash Income Expense-7,700,000-18,400,000-8,400,000
Change In Accounts Receivable23,000,000-121,200,000141,200,000
Change In Inventories-50,700,000256,100,000289,000,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable395,100,00089,500,000146,000,000
Change In Other Liabilities34,500,00021,400,00011,600,000
Cash From Operating Activities1,595,200,000542,300,000895,800,000
Purchases Of Marketable Securities3,091,800,000899,900,0009,100,000
Sales Of Marketable Securities2,816,000,000800,100,000617,900,000
Acquisition Of Property Plant And Equipment260,200,000252,400,000253,000,000
Acquisition Of Business———
Other Investing Activities7,400,00072,900,00012,500,000
Cash From Investing Activities-712,900,0002,312,900,000173,800,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock174,100,000179,500,000169,900,000
Repurchase Of Common Stock893,400,0001,159,400,000879,600,000
Issuance Of Long Term Debt——0
Repayment Of Long Term Debt——300,000
Other Financing Activities-3,800,000-3,100,000-1,000,000
Cash From Financing Activities-956,800,000-983,000,000-711,000,000
Change In Cash-119,300,0001,910,800,000375,400,000
Cash At End Of Period2,938,000,0003,045,200,0001,144,000,000
Income Taxes Paid490,400,0001,196,100,000470,100,000
Interest Paid20,200,00019,600,00019,900,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share1.846.982.31
Price To Earnings Ratio46.331510.60633.0087
Earnings Growth Rate-73.639202.1645-6.0976
Price Earnings To Growth Ratio-0.62920.0525-5.4134
Book Value Per Share17.677216.83611.0753
Price To Book Ratio4.82264.39716.8847
Ebitda1,700,100,0005,506,100,0002,035,000,000
Enterprise Value47,514,500,00041,800,231,00045,713,875,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.05790.05980.0898
Capital Expenditures282,500,00091,800,000261,500,000
Free Cash Flow1,312,700,000450,500,000634,300,000
Return On Equity0.10380.41750.2109
One Year Beta0.51840.79051.0607
Three Year Beta0.71050.94920.9904
Five Year Beta0.84740.96490.9886
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
BOBO DONALD E JRCVP,Strategy/Corp Development2026-03-0211,340A32,606
BOBO DONALD E JRCVP,Strategy/Corp Development2026-03-0211,340D21,266
BOBO DONALD E JRCVP,Strategy/Corp Development2026-03-0211,340D22,680
BOBO DONALD E JRCVP,Strategy/Corp Development2026-02-2524,000D21,266
Dahl Andrew M.SVP, Corporate Controller2026-02-22176D9,089
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Markwayne MullinSenator2024-09-19Sale (Partial)2024-08-20Joint$15,001 - $50,000
Markwayne MullinSenator2023-11-01Purchase2023-10-03Joint$1,001 - $15,000
Markwayne MullinSenator2023-10-12Purchase2023-09-13Joint$15,001 - $50,000
Thomas H TubervilleSenator2023-05-12Sale (Full)2023-04-03Joint$1,001 - $15,000
Thomas H TubervilleSenator2023-05-11Sale (Full)2023-04-03Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Josh Gottheimer2025-12-29NJ05Sale2025-11-19Joint$1,001 - $15,000
Jefferson Shreve2025-06-22IN06Sale2025-05-12—$50,001 - $100,000
Bruce Westerman2025-05-12AR04Sale2025-04-21—$1,001 - $15,000
Jefferson Shreve2025-05-08IN06Purchase2025-04-07—$15,001 - $50,000
Rob Bresnahan2025-05-08PA08Purchase2025-04-08—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
TOBAM2025-12-317,301,00085,64685.2462
Strategic Investment Solutions, Inc. /IL2025-12-3116,36819285.25
Anchor Investment Management, LLC2025-12-31996,40211,68885.25
Banque Transatlantique SA2025-12-312,668,02831,30185.2378
Bell Investment Advisors, Inc2025-12-3143,73451385.2515
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
PIMCO Equity Series2025-12-31PIMCO RAFI ESG U.S. ETFRAFE2,817240,149.250.2008
PIMCO Equity Series2025-12-31PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETFMFUS74363,340.750.0301
RYDEX SERIES FUNDS2025-12-31Class HRYNHX2,065176,041.250.0678
RYDEX SERIES FUNDS2025-12-31Class CRYNCX2,065176,041.250.0678
RYDEX SERIES FUNDS2025-12-31Class ARYANX2,065176,041.250.0678
This is a preview of the latest data. Subscribe to access the full data.